Glucagon-like peptide-1 (GLP-1) analogs have emerged as a compelling therapeutic strategy for managing metabolic conditions. These naturally occurring substances are secreted by the gut in response to nutrient intake, stimulating insulin secretion and suppressing glucagon release. GLP-1 derivatives possess promising therapeutic results in treating